PCSK9: Patients with high Lipoprotein (a) could benefit more

被引：0
|
作者：
Franke, Katharina
机构：
来源：
AKTUELLE KARDIOLOGIE | 2019年 / 8卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Effects of PCSK9 Inhibition on Plasma PCSK9 Concentration and Hepatic PCSK9 Expression
    Shapiro, Michael D.
    Tavori, Hagai
    Oleaga, Carlota
    Miles, Joshua
    Fazio, Sergio
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2018, 38
  • [22] PLASMA PCSK9 LEVELS AND LIPOPROTEIN DISTRIBUTION ARE PRESERVED IN PATIENTS WITH SEVERE HYPOALPHALIPOPROTEINEMIA
    Ruscica, Massimiliano
    Simonelli, Sara
    Botta, Margherita
    Ossoli, Alice
    Magni, Paolo
    Corsini, Alberto
    Arca, Marcello
    Pisciotta, Livia
    Veglia, Fabrizio
    Franceschini, Guido
    Ferri, Nicola
    Calabresi, Laura
    ATHEROSCLEROSIS, 2017, 263 : E91 - E91
  • [23] INHIBITION OF PCSK9 AFFECTS SERUM LIPOPROTEIN FUNCTIONS IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA
    Palumbo, M.
    Adorni, M. P.
    Zimetti, F.
    Pavanello, C.
    Giammanco, A.
    Cefalu, A. B.
    Noto, D.
    Piro, S.
    Di Pino, A.
    Averna, M.
    Calabresi, L.
    Bernini, F.
    Purrello, F.
    Scicali, R.
    ATHEROSCLEROSIS, 2022, 355 : E157 - E157
  • [24] Effect of PCSK9 inhibitor on lipoprotein particles in patients with acute coronary syndromes
    Li, Tingting
    Zhang, Yingyi
    Cong, Hongliang
    BMC CARDIOVASCULAR DISORDERS, 2021, 21 (01)
  • [25] Effect of PCSK9 inhibitor on lipoprotein particles in patients with acute coronary syndromes
    Tingting Li
    Yingyi Zhang
    Hongliang Cong
    BMC Cardiovascular Disorders, 21
  • [26] Lipoprotein Lipoprotein apheresis affects lipoprotein particle subclasses more efficiently compared to the PCSK9 inhibitor evolocumab, a pilot study
    Lappegard, Knut Tore
    Kjellmo, Christian Abendstein
    Ljunggren, Stefan
    Cederbrant, Karin
    Marcusson-Stahl, Maritha
    Mathisen, Monica
    Karlsson, Helen
    Hovland, Anders
    TRANSFUSION AND APHERESIS SCIENCE, 2018, 57 (01) : 91 - 96
  • [27] PCSK9: Structure and function. PCSK9 and low-density lipoprotein receptor. Mutations and their effects
    Pedro-Botet, Juan
    Badimon, Lina
    CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS, 2016, 28 : 3 - 8
  • [28] PCSK9
    Abifadel, M.
    Boileau, C.
    ATHEROSCLEROSIS SUPPLEMENTS, 2009, 10 (02)
  • [29] High glucose effects on PCSK9 expression in aortic VSMC: role of PCSK9 inhibitors
    Barale, C.
    Melchionda, E.
    Russo, I.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S421 - S421
  • [30] PCSK9 inhibition in patients with hypercholesterolemia
    Desai, Nihar R.
    Sabatine, Marc S.
    TRENDS IN CARDIOVASCULAR MEDICINE, 2015, 25 (07) : 567 - 574
12345